Key Takeaways
- €15 million (~$17M) raised: London-based JAAQ has closed a Series A round backed by Meridian Health Ventures, Fuel Ventures, Bolt Angels, and Guinness Ventures, bringing institutional firepower behind its mental health platform
- Leadership injection: Alex Packham, who sold ContentCal to Adobe for $100M+, has joined as CEO, adding a high-profile founder-operator pedigree to JAAQ’s growth phase
- Scale already proven: JAAQ has reached 1.5 million+ people, hosts 10,000+ clinically reviewed content pieces across 70+ topics, and already counts Bupa, NatWest, and Workday among its enterprise clients
- US expansion on radar: Proceeds will fund deeper US market entry, enterprise and healthcare system partnerships, and the build-out of JAAQ’s clinical and AI infrastructure
Quick Recap
In a fresh funding announcement confirmed by EU Startups and Alex Packham directly on LinkedIn, London-based JAAQ has closed a €15 million Series A round to accelerate its clinically governed digital mental health platform.
The round drew participation from Meridian Health Ventures, Fuel Ventures, Bolt Angels, and Guinness Ventures. Alongside the raise, serial entrepreneur and tech investor Alex Packham has formally stepped into the CEO role, signaling a clear shift from content-focused roots to a full-scale enterprise platform play.
Platform to Clinical Engine: JAAQ’s €15M Strategy
JAAQ, which stands for “Just Ask A Question,” started life as a free-to-use platform where users could receive expert video answers to mental health questions from world-leading clinicians and public figures. Under founder Danny Gray, the platform grew to answer over 250,000 questions and deliver more than 1 million minutes of mental health content to users across 140+ countries.
That origin story is now evolving fast. JAAQ has repositioned itself from a consumer content platform into the “JAAQ Platform,” a B2B infrastructure layer that embeds clinically governed mental health content and AI-powered behavioral journeys directly into digital products used by insurers, employers, and healthcare systems. The core proposition is that support should be embedded where people already are, not accessed through a separate app or behind a referral queue.
The €15 million Series A will fuel three specific growth vectors. First, JAAQ is going deeper on US expansion, targeting enterprise clients and health system partnerships beyond its current UK base. Second, it is scaling AI infrastructure to power personalized behavioral journeys at scale, combining clinical governance with machine-learning-driven user pathways. Third, the company is building out a sales and partnerships function to capitalize on growing demand from large employers, following early wins with clients like Bupa, NatWest, and Workday.
Notably, clinical governance is not a regulatory add-on for JAAQ; it is built into the product layer from day one. The platform maintains board-certified psychiatric oversight, all content is clinically reviewed, and crisis escalation protocols are embedded directly into every user journey. This sets JAAQ apart from generic employee wellbeing tools that treat safety features as afterthoughts.
Future of Digital Mental Health
The timing of JAAQ’s Series A is not accidental. The global digital mental health market was valued at approximately $27.55 billion in 2025 and is forecast to reach $58.67 billion by 2030, expanding at a CAGR of 16.3%. Projections from other analysts push the 2034 figure as high as $153 billion at an 18.58% CAGR, driven by AI integration, mobile-first access, and healthcare system demand for scalable solutions that require no new clinical headcount.
The NHS 10-year plan is accelerating digital health adoption at a pace not seen before, with AI moving from pilot to mainstream across diagnostics, clinical pathways, and patient monitoring. Meanwhile, traditional employee assistance programs (EAPs) continue to post utilization rates of just 5 to 15%, while JAAQ’s own platform reports activation rates above 35%. That gap is the commercial opportunity JAAQ is racing to capture.
The enterprise channel is especially important. JAAQ at Work, the B2B arm of the business, generated over £2 million in revenue in under a year of operation, and that commercial traction is what attracted institutional investors like Meridian Health Ventures, the first NHS-anchored and transatlantic venture capital fund. Meridian’s portfolio includes companies embedded inside Guy’s and St Thomas’, King’s College Hospital, UCL Hospitals, Cedars-Sinai, and Hartford HealthCare, giving JAAQ an immediate warm channel into large health systems on both sides of the Atlantic.
Bolt Angels, another participating investor, holds active board seats in JAAQ and has a stated target of 8x+ growth in enterprise value between 2025 and 2027. That ambition signals this is not a passive capital placement; backers are operationally engaged in scaling the company.
Competitive Landscape
JAAQ occupies a focused niche in the B2B mental health platform space. Its two most directly comparable competitors at a similar stage and product philosophy are Wysa and Unmind, both operating in the employer and healthcare system market with clinical validation as a core differentiator.
| Feature / Metric | JAAQ | Wysa | Unmind |
| Primary Model | Clinically governed video content + AI behavioral journeys, embedded B2B | AI chatbot (CBT-based) with live coaching layer | B2B workplace mental health platform with AI agent (Nova) |
| Total Funding Raised | ~$17M (Series A, 2025) | ~$40.14M across 23 rounds | $121.94M across 8 rounds |
| Enterprise Activation Rate | >35% (vs. EAP average of 5-15%) | Not publicly disclosed | Not publicly disclosed |
| Clinical Governance Model | Board-certified psychiatric oversight; all content reviewed; built into product layer | Clinically validated, FDA Breakthrough Device Designation for musculoskeletal pain | Clinical guardrails, outcomes tracking, AI-driven but therapy-integrated |
| Content Library | 10,000+ clinically reviewed pieces across 70+ topics | 150+ therapeutic exercises, CBT-based journeys | Proprietary AI agent Nova; coaching, therapy, digital interventions |
| Revenue Stage | £2M+ from JAAQ at Work in under 1 year | ~$4.68M 2024 revenue | ~$12.26M 2024 revenue |
| Key Enterprise Clients | Bupa, NatWest, Workday | NHS, employer health plans (US/UK/India) | Fortune 500 employers (US and EU) |
| US Expansion Status | Actively funding with Series A proceeds | Expanding in US, UK, and India post-Series B | $35M Series C (2025) focused on US scale |
Strategic Analysis
JAAQ leads on clinical governance depth and enterprise activation rates within its current client base, which makes it a compelling pitch to large insurers and health systems that demand outcomes accountability. Unmind, however, holds a significant revenue and funding advantage, having raised $121.94M and already operating at scale inside Fortune 500 employers.
Wysa’s FDA Breakthrough Device Designation gives it a regulatory head start for clinical settings, while JAAQ’s embedded platform model targets the activation gap that both competitors have yet to fully solve. At this stage, JAAQ’s strongest differentiator is not product breadth but the combination of clinical rigor and measurable engagement that most generic wellbeing tools cannot yet match.
Bayelsa Watch’s Takeaway
I will be honest: when I first read this announcement, my instinct was to categorize it as yet another mental health Series A in a crowded field. But the more I dug in, the more I think this one actually warrants attention.
Here is what stood out to me. Alex Packham is not a celebrity CEO brought in for optics. He built ContentCal from scratch, raised over £10 million, scaled it to 3,000 customers across 50 people, and sold it to Adobe for more than $100 million. He spent time as a strategic advisor to JAAQ before formally taking the CEO seat in April 2025. That transition arc suggests a genuine belief in the product, not a pay-to-lead arrangement.
I think the more interesting signal here is the investor syndicate. Meridian Health Ventures is NHS-anchored and has US hospital system relationships at Cedars-Sinai and Hartford HealthCare. Fuel Ventures backed ContentCal before the Adobe exit. Guinness Ventures also appeared in ContentCal’s cap table before that acquisition. This is not a fresh team; it is a group of investors who have already built and exited at least one company together with Packham. That pattern, in my experience, is a real signal.
